These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21314635)

  • 1. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.
    Florentin M; Liberopoulos EN; Kei A; Mikhailidis DP; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):385-400. PubMed ID: 21314635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
    Parhofer KG
    Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
    Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
    Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niacin and laropiprant.
    Sanyal S; Kuvin JT; Karas RH
    Drugs Today (Barc); 2010 Jun; 46(6):371-8. PubMed ID: 20571606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
    Olsson AG
    Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release niacin (nicotinic acid)/laropiprant.
    Perry CM
    Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What restricts the clinical use of nicotinic acid?
    Kei A; Liberopoulos EN; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):521-30. PubMed ID: 21314634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH; Cheung BM; Tse HF
    Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
    Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
    Markel A
    Isr Med Assoc J; 2011 Jun; 13(6):368-74. PubMed ID: 21809737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
    Offermanns S
    Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin fails to reduce vascular events in large randomised trial.
    McCarthy M
    BMJ; 2014 Jul; 349():g4774. PubMed ID: 25055803
    [No Abstract]   [Full Text] [Related]  

  • 20. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.